Inspirna

Oncology Therapeutics · Health Care
2 legal entities
Data updated Nov 20, 2026Money ledger: 4 records from 1 sourceFiled 4Full reportReport a mistake

Facts

as of Nov 20, 2026

News May 21, 2024 Inspirna Announces Appointment of Karim Benhadji, M.D., as Chief Medical Officer and Retirement of Robert Wasserman, M.D.

Legal name
Inspirna, Inc.
Headquarters
New York, United States
Employees
17US Form 5500 (plan participants) · Dec 2024
Legal entities
2 in 1 country
Register numbers
EIN 273120409

These are the key facts about Inspirna on Alion as of Nov 20, 2026. Inspirna is headquartered in New York, United States. It has raised $133.9M in 4 funding rounds. The latest round is Series D of $55.1M, announced in 2022.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Inspirna has $133.9M paid in by investors, lenders and donors.

$133.9MPaid in
Money innewest first
Equity raised
Jun 2022 · Series D
$55.1MPaid
Equity raised
Feb 2021 · Venture round
$6MPaid
Equity raised
Sep 2018 · Venture round
$39.8MPaid
1 more record: amounts, dates and sources of every round, loan and commitmentProUnlockor this company alone for 30 days · 50 credits
Money by yearUSD, rounds and grants
2022$55.1M1 record
2021$6M1 record
2018$39.8M1 record
2016$33M1 record
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".

Inspirna operates through 2 legal entities in 1 country.

Legal entities2 in 1 country
Inspirna, Inc.
operator · US EIN 273120409
US
Rgenix, Inc.
related
US
Holders and shares as each register or filing states them.

People

17EmployeesUS Form 5500 (plan participants) · Dec 2024

Products

Products →

Inspirna has 3 clinical trials on record, 0 under way.

Clinical trials
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
phase 2 · stopped or withdrawn · 76 participants · Colorectal Cancer; Metastatic Colon Cancer
Oct 2023
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
phase 1 · completed · 89 participants · Gastrointestinal Cancer; Gastrointestinal Neoplasms; Colorectal Cancer; Colorec…
Jun 2018
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
phase 1 · completed · 146 participants · Endometrial Cancer; Endometrial Cancer Recurrent; Lung Cancer Recurrent; Lung C…
Nov 2016
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.

Inspirna in public registers.

Legal entity active
Inspirna, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Patents
6
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Sources: the outlets named on each headline, each story once

Footprint

Hiring in 2 cities in 1 country.

2Cities
1Countries
Loading the map
SiteTypeOpen rolesHires most forEngineering
New York United StatesHeadquarters0
Long Island City United StatesRegional office0
Source: office addresses in postings and company registers